Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 4/20 | 0.50 |
| ▸ | CNR1 | P21554 | 3/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5839447 | 1.00 | CNR2 (0.50) | CNR2CNR1L3MBTL1RAB9AALDH1A1 | |
| SCHEMBL5840219 | 0.90 | L3MBTL1 (0.51) | CNR2CNR1L3MBTL1RAB9AALDH1A1 | |
| SCHEMBL5840224 | 0.90 | L3MBTL1 (0.51) | CNR2CNR1L3MBTL1RAB9AALDH1A1 | |
| SCHEMBL6063583 | 0.86 | CNR2 (0.58) | CNR2CNR1L3MBTL1 | |
| SCHEMBL8352815 | 0.86 | CNR2 (0.58) | CNR2CNR1L3MBTL1 | |
| SCHEMBL5778245 | 0.86 | CNR2 (0.57) | CNR2CNR1L3MBTL1ALDH1A1MAPK8 | |
| SCHEMBL5753745 | 0.86 | CNR2 (0.57) | CNR2CNR1L3MBTL1ALDH1A1MAPK8 | |
| SCHEMBL5782058 | 0.85 | L3MBTL1 (0.47) | L3MBTL1ALDH1A1GAATDP1MAPK8 | |
| SCHEMBL5782060 | 0.85 | L3MBTL1 (0.47) | L3MBTL1ALDH1A1GAATDP1MAPK8 | |
| SCHEMBL5839661 | 0.84 | CNR2 (0.50) | CNR2CNR1L3MBTL1ALDH1A1MAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7141586-B2 | Nicotinamide derivatives useful as PDE4 inhibitors | PFIZER INC. (US) | 2006-11-28 | — | — | US | disclosed |
| US-20050032838-A1 | Nicotinamide derivatives useful as PDE4 inhibitors | PFIZER INC. | 2005-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032838-A1 | Nicotinamide derivatives useful as PDE4 inhibitors | CBR3, CBR1, PDE9A | CNR2 88/4885CNR1 29/4885L3MBTL1 3803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.